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ABSTRACT
Malignant epithelial ovarian cancer (EOC) spheroids high frequently are detected in 
the malignant ascites of the patients with the extensive peritoneal metastasis of ovarian 
cancer, which represent a significant obstacle to efficacious treatment. Clinical data also 
suggested that EOC spheroids play a putative role in the development of chemoresistance. 
Since standard surgery and conventional chemotherapy is the only available treatment, 
there is an urgent need to identify a more effective therapeutic strategy. Recent 
studies demonstrated that curcumin exerts an anticancer effect in a variety of human 
cancers including ovarian cancer. This study evaluates anti-peritoneal metastasis and 
chemoresistance of curcumin related to the EOC spheroids. In this study, we confirm 
that the high invasive EOC cells forming the spheroids express a high level of a cancer 
stem cell (CSC) marker, aldehyde dehydrogenase 1 family member A1 (ALDH1A1), which 
was significantly down-regulated by curcumin treatment. Curcumin treatment markedly 
enhances the sensitivity of EOC spheroids to cisplatin in a dose-dependent manner. Our 
experiments provided evidence that curcumin could abolish the sphere-forming capacity 
of EOC cells in a dose-dependent manner. Moreover, curcumin substantially suppressed 
the growth of the pre-existed EOC spheroids, inhibited the adhesion of EOC spheroids 
to ECM as well as the invasion of EOC spheroids to the mesothelial monolayers. We 
propose to re-purpose curcumin as anti-metastatic and chemoresistant agent for EOC 
management in combination with conventional regimen. Further preclinical studies are 
necessary to validate the anti-cancer effect of curcumin in patients with EOC.
INTRODUCTION
Epithelial ovarian carcinomas (EOCs) accounts 
for nearly 90% of all malignant ovarian tumours and is 
the leading cause of death from gynaecologic malignant 
tumour [1]. In contrast to most other solid tumours, the 
majority of EOC patients already are at the advanced 
stages (III or IV) disease when diagnosed. A current 
standard treatment for the patients with advanced ovarian 
cancer includes primary tumour cytoreductive surgery 
followed by cisplatinum-based chemotherapy since 1970 
[2, 3]. Cisplatin is administrated intravenously to cause 
DNA crosslink, leading to apoptosis of cancer cells. 
Although the current therapies for EOCs have dramatically 
been advanced recent years, approximately 85% of patients 
with EOCs will have recurrent disease within 2 years and 
become resistant to cisplatin. Therefore, there is an urgent 
need to develop new therapeutic strategies for improving 
the efficacy of treatment of EOCs, including cisplatin. 
Clinical observations suggest that there is a high 
incidence of the free-floating multicellular tumour 
spheroid superficially invading to the peritoneal cavity. 
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In fact, ovarian cells move around readily within the 
peritoneal cavity via the peritoneal fluid under normal 
condition. Similarly, the cells shed from the primary 
EOCs, individually or in multicellular spheroids, are 
carried by the peritoneal fluid (ascites) and migrate onto 
the peritoneal mesothelium [4, 5], followed by sequential 
fast growth of tumour nodules. A study has found that the 
spheroid formation might enrich for cells with the cancer 
stem cells (CSCs)-like phenotype [6]. These CSCs can 
maintain an aggressive phenotype for an extended period 
even in vitro anchorage-independent culture as well as 
to form xenograft ovarian cancer in immune-deficient 
mice [7]. Failure to target tumour spheroids and eradicate 
the CSCs led to the development of chemoresistance 
or radioresistance and the disease relapse, represents a 
significant bottleneck to efficacious treatment [8]. 
Curcumin is a well-known derivative of the plant 
rhizome Curcuma longa with many pharmacological 
effects (i.e. anti-inflammatory, anti-oxidant, anti-bacterial 
and antiviral) [9]. Also, extensive studies showed that 
curcumin exerts cytotoxic effects on a variety of tumour 
types, including melanoma [10], medulloblastoma [11], 
breast [12], colorectal [13], pancreatic [14] and ovarian 
cancer [15]. Curcumin can inhibit cancer cell invasion, 
metastasis and angiogenesis [16] via modulating many 
signalling pathways (e.g., NF-κB [17], Akt/mTOR [18] 
and HIF1α [19]. More studies implicate that curcumin 
might influence the self-renewal pathways of cancer stem 
cells including Wnt/β-catenin [20], sonic hedgehog (SHH) 
[21]and Notch [22]. Nevertheless, many clinical trials 
reported no toxicity to human treated with curcumin at a 
moderate dose for several months [23].
In the present study, we generated spheroids for 
EOC cell lines. These high invasive sphere-forming cells 
express aldehyde dehydrogenase 1 family member A1 
(ALDH1A1), indicating a possible enrichment of the cancer 
stem cells. Our data showed that curcumin could enhance 
the efficacy of cisplatin on ovarian cancer cells. We found 
that curcumin could suppress the EOC spheroid forming 
at dose-dependent manner with a reduction in ALDH1A1 
expression. The ovarian cancer spheroids exhibit a 
significant increase in abilities of adhesion and invasion, 
which also can be inhibited by curcumin treatment. More 
interestingly, curcumin exerts an inhibitory effect on 
the ovarian cancer spheroids invading the mesothelial 
monolayers. This study provides evidence to re-purpose 
curcumin as an anti-metastatic agent for the treatment of 
peritoneal metastatic EOCs.
RESULTS
Spheroid formation of EOCs
Many different methods have been explored for 
tumour sphere formation, but the basic condition is to 
make the adhesive forces between cells greater than for 
the surface on the culture ware [24]. In this study, we 
adopted an anchorage-independent approach (described 
in Materials and Methods). Two ovarian cancer cell lines 
with different aggressiveness [SKOV3 (high invasive) 
and OVCAR3 (low invasive)] were trypsinised from 
the monolayer cultures and inoculated on an ultra-low 
attachment (ULA) 96-well plate. Our data showed that 
the two ovarian cancer cell lines exhibited different 
characteristics on the spheroid formation. A loose 
multicellular spheroid was observed in SKOV3 cells in 
this 3-dimensional culture condition for 6 hours, which 
dispersed upon pipetting, followed by a further tightening 
of the aggregates after two days and reaching a plateau 
level by day 7 (Figure 1A, 1C). In contrast, OVCAR3 cells 
formed the compacted spheroids much quick than SKOV3 
cells (Figure 1B, 1C). However, after 72 hours, the 
OVCAR3 spheroid underwent a self-dissociated process 
(Figure 1C). Nevertheless, we successfully obtained 
sustainable spheroids from two ovarian cancer cell lines, 
which were subjected to the subsequent experiments as 
indicated.
Enrichment of cancer stem cells in sphere-
forming ovarian cancer cells 
Development of ovarian cancer chemoresistance 
is driven by multiple mechanisms. There is an increased 
evidence indicating that ovarian CSC might be 
another crucial link for ovarian tumour cells becoming 
chemoresistance and metastatic. The previous study 
demonstrated that the spheroids formed from the surgical 
specimen of cancer express CSC markers depending the 
tumour types. In colorectal liver metastases, for instance, 
the spheroid forming capacity was reflected by the order of 
expression of group genes such as ALDH1A1high﹥CD133
﹥CD26 [25]. Several of the characteristic CSC markers 
for ovarian cancer have been identified, among which 
high levels of ALDH1A1 are correlated with the sphere 
formation [26]. ALDH1A1 has been found to be up-
regulated in EOC cells [27]. Since EOC cells exhibit more 
significant capacity of sphere-forming, we determined 
whether ALDH1A1 can be enriched during the EOC 
spheroid formation. Indeed, our Western blot analysis 
demonstrated that ALDH1A1 expression significantly was 
upregulated in the both sphered-formed EOC cells (SKOV3 
and OVCAR3) compared to the monolayers of counterparts 
(Figure 2A and 2C). 
Cytotoxic effects of curcumin on ovarian cancer 
cells with sensitizing ovarian cancer spheroids to 
conventional therapy
Considering cell viability and cellular association 
are strongly interrelated, and both mechanisms might 
be major contributors to cancer sphere formation, we 
investigated whether curcumin affects the viability of 
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the ovarian cancer cells. We treated both SKOV3 and 
OVCAR3 spheroids with different concentrations of 
curcumin for 48 hours. MTT assay showed that curcumin 
causes modest cytotoxicity in both SKOV3 and OVCAR3 
cells from the spheroids with the IC50 at 60 μM and 
105 μM, respectively (Figure 3A). Intriguingly, incubation 
with curcumin more effectively reduced viability in both 
SKOV3 and OVCAR3 cells under adherent monolayer 
cultures with the IC50 at 25 μM and 35 μM, respectively 
(Figure 3B).
Meantime, we found that there is a difference in the 
inhibitory effects of cisplatin on the SKOV3 cells between 
in monolayer cultures and spheroids. To determine 
whether the spheroid formation of ovarian cancer cells 
conferred their chemoresistance, we treated both the 
SKOV3 cell monolayers and spheroids with cisplatin for 
48 hours. As shown in Figure 4A, the SKOV3 spheroids 
require a higher concentration of cisplatin (6 µg/ml≈ 
20 μM) to achieve the 50% inhibition of cell growth than 
the SKOV3 in monolayer culture (3 µg/ml≈10 µM).
Figure 1: Generation and proliferation of compact spheroid from the EOC cell lines. EOC cells were seeded in the ULA 
96-well plate. Aggregation of cells was viewed using the light microscopy at a time course (0, 6, 24, 48 and 72 hours, 5 and 7 days). 
(A) Representative images of SKOV3 spheroids; (B) Representative images of OVCAR3 spheroids. Scale bar = 500 µm (C) Quantification 
of the density of EOC spheroids. The density of SKOV3 spheroids increased. By 48 hours the compaction was completed for SKOV3 
cell line. Further tightening of the aggregates can be observed after two days, which could not be dissociated by pipetting. OVCAR3 cells 
were found to have a tendency of forming compacted spheroid much quick than SKOV3 cells. One day after plating, OVCAR3 cells 
formed compact spheroid which could not be dissociated by pipetting. However, after 72 hours when the cell density of SKOV3 spheroids 
remained a compact structure, the OVCAR3 spheroid underwent a self-dissociated process. Results were expressed as the mean ± SEM 
from at least three experiments.
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Given that cisplatin and curcumin have shown 
some degrees of toxicities to the SKOV3 spheroids, it is 
logical for us to assess what combine effects of cisplatin 
and curcumin treatment on SKOV3 spheroids. Of 
particular interest is to identify whether synergism when 
both drugs tested in combination. We adopted for Bliss 
independence models for drug interaction. As shown 
in Figure 4B, additive model was observed at the range 
(< 40 µM, > 60 µM) of drug concentrations, whereas the 
combination seems to display Bliss synergism at 40 and 
60 µM. Our data further demonstrated that combined 
with curcumin (60 µM), 2 µM of cisplatin (equivalent to 
0.5 µg/ml) exerted ~50% of inhibitory effects on SKOV3 
spheroids (which can be only achieved by cisplatin alone 
at 20 µM≈6 µg/ml) (Figure 4C), suggesting that the 
combination of curcumin might sensitize ovarian spheroids 
to conventional chemotherapy and a significant reduction 
in dose of conventional chemoagents.
Inhibitory effects of curcumin on spheroid 
formation of ovarian cancer cells
To investigate whether curcumin affects the sphere-
forming of ovarian cancer, we examined the fluorescent 
densities of EOC spheroids formation for 2 days in culture. 
The fluorescent staining shows an intensive rim area of 
SKOV3 spheroid with a less densely middle section (the 
top left-hand panel at Figure 5A), whereas OVCAR3 cells 
exhibited more even intensity over the spheroids, (the top 
right-hand panel at Figure 5A). We found that curcumin 
exhibits an inhibitory effect on the compaction of the 
ovarian cancer spheroids at a dose-dependent manner 
(Figure 5B). Curcumin completely impairs the round 
geometry of the tighten spheroids at 60 µM for SKOV3 
and at 120 µM for OVCAR3 (Figure 5B). 
Since curcumin is a potent inhibitor of the ovarian 
cancer sphere formation, we performed western blot 
analysis to determine whether curcumin can modulate 
ALDH1A1 expression in ovarian cancer spheroids. 
Curcumin treatment (60 μM) resulted in a significant 
reduction in ALDH1A1 expression with completely 
disrupting the sphere formation of EOC cells (Figure 2B 
and 2D). These data confirm that curcumin might act as a 
promising agent targeting the cancer stem cells.
Curcumin inhibits the EOC spheroids adhering 
and invading to the extracellular matrices 
(ECM)
Progression of ovarian cancer cells involves 
adhesion and interaction with the extracellular matrix of 
the surrounding tissues. In this study, we used adhesion 
and invasion assays, in which cells need to adhere or break 
down the Matrigel mimicking the cells interactive with 
the extracellular matrix (ECM) in vivo. We analysed the 
adhesion and invasion assay for malignant EOC cell line-
SKOV3 cells (either in monolayer or spheroid cultures). 
SKOV3 spheroids exhibited significantly adhesive to 
the Matrigel (p < 0.05) after being added for 45 minutes 
compared with SKOV3 in the monolayer culture 
(Figure 6A). For the invasion assay, the SKOV3 cells 
both in monolayer culture and spheroids were added onto 
the Matrigel-coated membranes (inserts) for 48 hours. 
Similarly, compared the SKOV3 cells in monolayer 
culture, the SKVO3 spheroids exhibited significantly 
increased ability to invade across the Matrigel membrane 
(p < 0.05) (Figure 6A), These data indicated that ovarian 
cancer cells obtained more aggressive properties after 
forming spheroids, supporting the notion of the increased 
metastatic attributes of a tumour spheroid.
We assessed whether curcumin exert anti-adhesion/
invasion effects on ovarian cancer spheroids. The tested 
doses of curcumin were 30, 60 and 120 µM. After treated 
with curcumin for 48 hours, a dose-dependent reduction 
in the adhesion of SKOV3 spheroids to the Matrigel 
was observed and the reduction was highest at 120 µM 
(Figure 6B). As shown in Figure 4B, curcumin reduced the 
invasion ability of SKOV3 spheroids dose-dependently, 
with a maximum decrease ~90% (p < 0.05) at 120 µM. 
The data showed that curcumin significantly decreased 
spheroid-ECM adhesive and invasive capacities at a dose-
dependent manner (Figure 6B).
Inhibitory effect of curcumin on EOC spheroids 
invading the mesothelial monolayers
Since all of the organs within the peritoneal cavity 
are covered with a continuous single layer of mesothelial 
cells, a critical step for the peritoneal cancer metastasis is 
for cancer cells to sustain proliferative and invasive abilities 
after adhered to the mesothelium. In the attempt to better 
understand whether curcumin affects the invasive behaviour 
of EOC spheroids onto the mesothelial cells of peritoneal 
cavity, we directly analyzed SKOV3 spheroids interactions 
with human mesothelial cell (LP-9) monolayers. LP-9 cells 
were labelled with CellTracker™ Orange CMRA (red) while 
the SKOV3 spheroids were labelled with CellTracker™ 
Oregon Green 488 (green). Followed by adhering, the 
invading edges of the spheroids push the mesothelial 
cells aside clearing off an acellular area in the monolayer. 
The resultant area, then, can be measured as mesothelial 
clearance. After 24 hours of co-cultured with the SKOV3 
spheroids, the LP-9 monolayers exhibited a considerable 
size of acellular area compared to the original size of the 
spheroids (Figure 7A, the top two panels). As shown in 
Figure 7A (the bottom two panels), there were much smaller 
acellular area created by the SKOV3 spheroids pre-treated 
with curcumin (30 µM for 48 hours). As Figure 7B shown, 
curcumin may exert a significant inhibitory effect on the 
mesothelial invasiveness of ovarian cancer spheroids. 
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DISCUSSION
EOCs are responsible for approximately 90% of all 
ovarian cancer cases and derived from ovarian surface 
epithelium stem cells or fallopian tube epithelium. 
Despite decades of medical advances, ovarian cancer is 
still associated with high number of patients having a 
relapse of their disease. Strong evidence suggests that 
a rare subpopulation of cancer cells called ‘cancer stem 
cells’ (CSCs) is responsible for the escaping the current 
chemotherapy and tumour recurrence. Therefore, targeting 
CSCs represents an important strategy to greatly improve 
current cancer treatment.
The accumulated data suggest that cancer sphere-
formation is able to enrich dominant self-renewal of 
the CSC population. It has been demonstrated that 
only cells forming spheroids in anchorage-independent 
conditions, but not the adherent cells, could be returned to 
exponential growth under normal culture conditions and 
then back to spheroid conditions to reform spheroids [6]. 
In order to study EOC tumorigenesis, we generated 
self-renewing spheroids when EOC lines were grown 
Figure 2: Increased ALDH1A1 expression in EOC spheroids. (A) (C) Western blot data showed a high expression levels 
of ALDH1A1 in SKOV3 spheroids and OVCAR3 spheroids. (B) (D) Curcumin at 60 µM reduced ALDH1A1 expression in SKOV3 
spheroids and OVCAR3 spheorids. GAPDH was used as an internal control. Results were expressed as the mean ± SEM from at least three 
experiments. *P < 0.05.
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in anchorage-independent conditions. These spheroids 
morphologically are resemble to spheroids isolated from 
patient ascites. Although the resultant spheroids enriched 
of CSCs are heterogeneous, these spheroids could restore 
to exponential growth under normal adherent culture 
condition, and then much easily form spheroids when 
returned to anchorage-independent conditions (Data no 
shown). Extensive studies revealed that hypoxia, nutrient 
deprivation, abnormal distribution of metabolites and 
cell-cell interactional signalling molecules is difficulty 
to be recapitulated in two-dimensional (2D) monolayer 
of cancer cell cultures. In contrast, three-dimensional 
(3D) structures provide a spatial and temporal insights 
on how cancer cells exposure to heterogeneous oxygen 
and nutrients, but also mimic a chemoagent gradient [28]. 
Nevertheless, cellular behaviour and treatment response 
comparisons of CSC and non-CSCs often have to be made 
between cells propagated in different conditions (spheroids 
versus adherent growth). Many studies have successfully 
identified ovarian CSCs based on the expression of 
stemness markers. For instance, aldehyde dehydrogenase 
1 family member A1 (ALDH1A1) ALDH1A1 has been 
exploited to define CSC subpopulations in ovarian cancer 
[27]. ALDH1A1 positive cells isolated from ovarian 
cancer cell lines are chemoresistant and significantly 
more tumorigenic capacity than ALDH1A1 negative 
cells. However, these ovarian CSC markers seem not 
to be good candidates for CSC-targeting due to these 
differential expressed cell surface markers having not been 
functionally linked with ovarian CSC properties such as 
self-renewal or differentiation [29].
The current model of EOC peritoneal metastasis 
includes three steps. Firstly, cells need to leave from the 
primary tumour. Then, cells are transiting in the peritoneal 
Figure 3: Cytotoxic effects of curcumin on SKOV3 and OVCAR3 monolayers and spheroids. Cells were treated with 
different concentrations (as indicated) of curcumin for 48 hours. Cell viability was examined by MTT assay. Cytotoxic effects of curcumin 
on (A) EOC spheroids and (B) monolayer cultures. Results were expressed as the mean ± SEM from at least three experiments. *P < 0.05, 
compared with negative control.
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Figure 4: Curcumin sensitized SKOV3 spheroid to cisplatin treatment. (A) The response to the cisplatin was examined in 
monolayer and spheroid by using MTT assay. Results showed represent the average in cell viability from three experiments with triplicates, 
± SEM. *P < 0.05, spheroid vs. monolayer. (B) Bliss independence models for cisplatin and curcumin interaction indicated that additive 
model was observed at the lower range of drug concentrations (< 40 µM or > 60 µM), whereas the combination seems to display Bliss 
synergism at concentrations (of 40 µM and 60 µM). (C) The combined with curcumin (60 µM), 0.5 µg/ml of cisplatin (equivalent to 
3.33 µM) exerted ~50% of inhibitory effects on SKOV3 spheroids (which can be only achieved by cisplatin alone at 16 µg/ml) and 
combination of these two agents. Results were expressed as the mean ± SEM from at least three experiments. *P < 0.05, compared with 
negative control.
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cavity. Although both single cell and spheroid cells are 
contributed to the metastasis, it has been proposed that 
spheroid possesses increased invasive ability [7]. The final 
step is invaded the mesothelial lining and grow as a second 
lesion [30, 31]. We speculated that our sphere-formation 
approach might also have advantage of dissecting ovarian 
cancer peritoneal metastasis. A recent report has shown 
highly correlation between a selective increase in CSCs 
spheroids and peritoneal metastasis [32]. Also, cancer 
spheroid cells are well known to have a great tendency 
to tolerate many chemoagents than their monolayer 
counterparts. In general, these spheroids possess rough-
rounded morphology and the capable of keeping intact 
as free-floating conditions. Since it is believed that the 
established ovarian cancer cell line do not necessarily 
reflect in vivo conditions, many sophisticated heterotypic 
ovarian cancer spheroids containing stromal cells have 
been reported. However, co-cultured with different types of 
cells the ovarian cancer cells are difficult to form spheroids 
with standardized mass production [33]. Nevertheless, we 
observed that the single ovarian cancer cell-formed spheroids 
can lead to reproducible sphere formation within similar size, 
which makes these spheroids ideal for drug testing.
Despite numerous compounds have shown pre-
clinical promise as new ovarian cancer therapeutic 
agents no drugs have successfully improved the overall 
survival for the patients with ovarian cancer during the 
past 30 years [34–36]. Addition to the lack of response, 
Figure 5: The inhibitory effects of curcumin on SKOV3 and OVCAR3 sphere formation. The SKOV3 and OVCAR3 
cells formed spheroid in different concentrations (as indicated) of curcumin for 48 hours. The process of sphere formation was observed 
at 6 hours and 48 hours. (A) Representative images of sphere-forming SKOV3 (the left-hand panel) and OVCAR3 cells (the right-hand 
panel). Calibrated images were used to obtain morphometric data to determine spheroid area. (B) The changes of EOC spheroid area were 
normalized to spheroid area at 6 hours. Results were expressed as the mean ± SEM of at least experiments. *P < 0.05, compared with 
curcumin 0 μM. Scale bar = 500 μm.
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chemoresistance may result in use of high-dose 
chemoagents, leading to unnecessary toxicities to normal 
host tissues/cells, some of which are even fatal. Thus, the 
identification of nontoxic agents that specifically target 
the CSC enriched ovarian cancer spheroids may serve 
as a novel therapeutic avenue to improve the efficacy of 
current chemotherapeutic agents, which in turn leading 
to reducing the risk of relapse and peritoneal metastasis. 
Curcumin is extensively used as a flavouring agent in 
food supplements and is responsible for giving turmeric 
spice yellow colour. Curcumin directly interacts with 
several molecular proteins including inflammatory 
molecules, cell survival proteins, histone acetyltransferase 
(HATs), histone deacetylase (HDAC), protein kinase 
and reductase, glyoxalase (GLOI), proteasome, 
sarcoplasmic reticulum Ca2+ ATPase (SERCA), human 
immunodeficiency virus type 1 (HIV1) integrase and 
protease, DNA mehtyltransferases 1 (DNMT1), FtsZ 
protofilaments, carrier proteins, DNA, RNA, and metal 
ions [37]. Curcumin also interacts indirectly with 
several transcription factors including nuclear factor-
kappa-B (NF-κB), activator protein 1 (AP-1), β-catenin, 
signal transducer and activator of transcription (STAT) 
protein, and peroxisome proliferator-activated receptor 
y (PPARy) (Figure 8). Recently, it has become clear 
that curcumin, the major derivate of turmeric, has no 
detectable toxicities [23], but still induces chemo-/
radio-sensitization in ovarian cancer cells by enhancing 
their apoptosis [38]. Our study confirmed that curcumin 
treatment resulted in an enhancement in inhibitory effect 
of cisplatin on the viability of the ovarian cancer cells. 
Furthermore, we demonstrated a novel inhibitory effect 
of curcumin on ovarian cancer cells through affecting 
the ovarian cancer spheroids. Recent studies demonstrate 
that curcumin affects the extracellular matrix (ECM), 
adhesion molecules via regulation of PI3K/Akt, ERK and 
PTEN signalling pathway [39] (Figure 8). Using a single 
ovarian cancer cell-forming multicellular spheroids, 
Figure 6: The inhibitory effect of curcumin on aggressive capacity of SKOV3 spheroid. (A) Comparison of adhesion and 
invasion of SKOV3 between monolayer and spheroid. Cells grown as spheroid for 2 days were trypsinized to a single cell suspension 
and allowed to adhere or invade to the matrigel. *P < 0.05, compared with monolayer. (B) Adhesion and invasion assays were performed 
in SKOV3 spheroid after curcumin treatment. Scale bar =125 µm. All the data were presented as the mean ± SEM of at least three 
experiments.*P < 0.05, compared with negative control.
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we revealed that curcumin induced the inhibition of 
sphere formation corresponded with downregulation of 
proliferation, adhesion to and/ or invasion through the 
extracellular matrix (ECM). Most importantly for the 
first time curcumin was shown to attenuate ALDH1A1 
expression in the EOC spheroids. Moreover, we observed 
that curcumin decreased the mesothelial clearance ability 
of the spheroid, suggesting that curcumin prevents ovarian 
cancer cells invasion at metastatic site. 
In conclusion, we confirmed that the sphere 
formation plays a vital role in peritoneal metastasis 
and chemoresistance in epithelial ovarian cancer. We 
highlighted the therapeutic value of intervening the 
ovarian cancer spheroids in the inhibition of peritoneal 
metastasis. Targeting both the sphere formation and 
cancer stemness might be another promising strategy 
in overcoming chemoresistance in ovarian cancer 
management. Collectively, our results provide clear 
evidence of the therapeutic potential of curcumin as an 
adjunct to conventional chemotherapy in the ovarian 
cancer patients with peritoneal metastasis and/or being 
resistance to conventional chemoagents. Our findings 
strongly support the effort to re-purpose curcumin as anti-
metastatic therapeutic agent for EOC.
Figure 7: The inhibitory effects of curcumin on ovarian cancer spheroids invading the mesothelial monolayer. 
Followed by adhering, the invading edges of the spheroids push the mesothelial cells aside clearing off an acellular area in the monolayer. 
(A) Representative images of immunofluorescence for SKOV3 spheroid (Green) invading mesothelial monolayer (Red) for 24 hours. 
(B) Quantification of the clearance areas on mesothelial monolayers by curcumin. All the data were presented as the mean ± SEM of at least 
three experiments. *P < 0.05, compared with negative control. Scale bar = 500 μm. 
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MATERIALS AND METHODS
Spheroid formation of EOCs
The SKOV3, OVCAR3 human epithelial ovarian 
cancer (EOC) cell lines were purchased from ATCC 
(Rockville, MD, USA). The SKOV3 cells were cultured in 
DMEM/F12 HAM (Dulbecco’s modified Eagle’s medium; 
Sigma-Aldrich), supplemented with 10% foetal calf serum 
(FCS; PAA Laboratories, Somerset, UK), 100 μg/ml 
streptomycin, and 100 U/ml penicillin (Sigma-Aldrich) 
and aseptically grown at 37°C in a humidified incubator 
containing 5% CO2. The OVCAR3 cells were cultured in 
1640 medium (Sigma-Aldrich), supplemented with 10% 
FCS, 100 μg/ml streptomycin, and 100 U/ml penicillin 
and aseptically grown at 37°C in a humidified incubator 
containing 5% CO2.
In order to generate spheroid, the SKOV3 and 
OVCAR3 cells were typsinised and cultured in 96-well 
ultra-low attachment (ULA) cluster plate (Greiner Bio-
One, Germany) at a density of 2 × 104 or 5 × 104 cells/
well, respectively and aseptically grown at 37°C in 
a humidified incubator containing 5% CO2. The half 
of medium (100 μl) was replaced by the fresh medium 
every two days. The sphere formation was maintained for 
6 hours, 24 hours, 48 hours, 72 hours, 5 days and 7 days, 
respectively, subjected to sequential relevant experiments. 
Spheroid formation was continuously monitored in for one 
week using a Leica microscope (Leica CM1900) and Las 
EZ image capture software to take photographs. The cell 
density of each spheroid was quantified by an eyepiece 
systemic point-sampling grid as described previously 
[40], which contains 100 and 50 lines to count the number 
of points overly cell nuclei at 400 × mangification. 
Measurement were averaged over five microscopic fields 
to obtain an indexed percentage.
In order to assess the spheroid formation, the 
monolayer cells were dyed with CellTrackerTM Orange 
CMRA (1 μg/ml, 37°C, 20 minutes) (Life Technologies), 
and then trysinsied, followed by cultured in 96-well 
ULA plate at the density of 2 × 104 (SKOV3) or 5 × 104 
(OVCAR3) cells/well. Spheroid formed was visualized 
using a confocal Leica microscopy and photographed 
using a Hamamatsu digital camera. The area of each 
spheroid was measured by Image-J software. Area fold 
was calculated by dividing the final area of spheroid at 
time 48 hours by of the spheroid at time 6 hours (Area 
Ratio = Spheroid Area48h / Spheroid Area6h).
Western blot analysis of cancer stem cell marker
Total cellular protein was isolated from monolayer 
and spheroid EOC cells. Briefly, the SKOV3 cells of 
each group were wash with ice-cold PBS twice and lysed 
in a buffer comprising 50 mM Tris-base, 5 mM EGTA, 
150 mM NaCl, 1% Triton X-100, 100 μg/ml PMSF, 
Figure 8: Schematic diagram showing the possible signalling pathways related to the inhibitory effect of curcumin 
on ovarian cancer development. Curcumin inhibits the activities of Akt/mTOR, ERK1/1, leading to induction of autophagy, while 
ROS production is rendered by curcumin, resulting in activation of apoptotic signaling [18]. Taken together, curcumin exerts inhibition 
of ovarian cancer cell proliferation. Curcumin reduces the stemness of ovarian cancer cells through downregulation of Wnt/β-catenin 
[20], Sonic Hedgehog [21] and Notch pathways [22]. Curcumin inhibits the adhesion and invasion of ovarian cancer cells to peritoneal 
mesothelial lines via inhibition of NFκβ signaling activation [17]. Akt (pathway): a serine/threonine kinase involving cell survival and 
growth; ROS/RNS: Reactive Oxygen Species and Reactive Nitrogen Species; Wnt/β-catenin: a group of signal transduction pathways 
associated with tumour development; NFκβ: nuclear factor κ beta.
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10 μg/ml aprotinin, 10 μg/ml leupeptin, 5 mM sodium 
vanadate and 50 mM sodium fluoride, then clarified 
by centrifugation (13000 rpm, 15 minutes, 4°C), and 
quantified by DC Protein Assay kit (Bio-Rad Laboratories, 
Hertfordshire, UK). Thirty µg of protein extract per lane 
were separated by SDS-PAGE using 10% gels. Proteins 
were transferred onto a PVDF membrane and blocked 
with 5% non-fat milk. Then PVDF membrane was 
incubated with respective primary antibodies directed 
against ALDH1A1 (1:2000) (Sigma-Aldrich) and 
GAPDH (1:3000) (Biosciences, San Diego, CA, USA) 
at 4°C overnight. Immunoreactive bands were visualized 
by incubating with HRP-conjugated mouse or rabbit 
anti-IgG (1:3000) (Santa Cruz Biotechnology, Inc., 
CA, USA) for 1 hour at RT, then followed by exposure 
to enhanced chemiluminescence reagent (Luminata 
chemiluminescence detection kit, Merck-Millipore).
In vitro cytotoxicity (MTT) assay
10 μl of the MTT solution (Sigma-Aldrich) was 
added to each well, and the plates were incubated for 
4 hours at 37°C. In monolayer cultures, the medium 
was removed and added 150 μl DMSO to dissolve the 
formazan crystals. In spheroid cultures, the formazan 
crystals were collected by centrifugation (13000 rpm, 
10 minutes), dissolved in DMSO. The absorbance was 
quantified using a Bio-Tek Elx800 multi-plate reader (Bio-
Tek Instruments Inc., VT, USA) at 540 nm. 
Drug treatments
Curcumin (Sigma-Aldrich) was dissolved in 
dimethylsulfoxide (DMSO) to make a 40 mM stock 
solution and was added directly to the media at different 
concentrations. Cells were treated with 0.3% DMSO as the 
negative control. The dosing of curcumin we chose in this 
study was based on previous reports [41, 42].
24 hours after seeding in 96-well plate as monolayer 
cultures or spheroids, the SKOV3 cells were treated with 
curcumin (0–100 μΜ for the monolayer culture and 
0–200 μΜ for the spheroids,) cisplatin (0–100 μM for 
both monolayer culture and the spheroids) for 48 hours, 
subjected to the sequential relevant experiments.
In order to assess the combined effects of cisplatin 
and curcumin on the ovarian cancer spheroids, the 
responses were measured by Bliss independence reference 
models of synergy [43], using Graphpad Prism® (Version 
6.01, GraphPad Software, San Diego California USA, 
http://www.graphpad.com). The Bliss independence model 
is defined by the equation: Fab = Fa + Fb – Fa × Fa for 
0 < F < 1. The fractional response to drug A alone at any 
dose is Fa. Similar the fractional response to drug B alone 
is Fb. Fab is the total response to a mixture of the two 
drugs. The combined effects of the two drugs as predicted 
by their individual effects Fa and Fb. The dose-response 
curve for drugs A and B administrated together is very 
close to the sum of the two individual dose-response 
curves, the combined effects are conforms to the additive 
model. In contrast, the combined effects are defined as 
synergistic model if the dose-response curve of Fab is 
larger than the sum of the two individual dose-response 
curves. In this case, Fa is the response curve for cisplatin 
while Fb is the response to curcumin. Fab would be the 
combined effects of cisplatin and curcumin.
Adhesion assay
In preparation for the assay, a 96-well plate was 
pre-coated with 5 µg Matrigel (BD Matrigel matrix, 
Matrigel basement membrane matrix, Biosciences) 
diluted in DMEM/F12 HAM without FCS. The SKOV3 
cell suspensions for monolayer and spheroid at density 
of 2 × 104 cells/well in complete media were added into 
each well and left to adhere at 37°C, with 5% CO2 for 
45 minutes. Then the wells washed with PBS to remove 
any unbound cells. The cells that had remained adhered 
were fixed with 4% formalin and stained with 0.5% 
crystal violet. The adherent cells were visualized under 
the microscope and counted by the image-J. The number 
of seeding cells was adjusted by the trypan blue (Seeding 
cells = 2 × 104 cells/cell viability rate).
Invasion assay
In preparation for the assay, a 24-well Transwell 
insert with 8.0 µm pore size (Greiner Bio-One, Germany) 
was pre-coated with 50 µg Matrigel diluted in DMEM/
F12 HAM without FCS. The SKOV3 cell suspensions 
for monolayer and spheroid (2 × 104 cells/well in 
serum-free growth media + 0.1% FCS) were added to 
the upper compartment of the insert. Media containing 
a chemoattractant (10% FCS) was added to the bottom 
chamber of the Transwell plates. Following incubation at 
37°C for 48 hours, non-invaded cells (which remained on 
the upper surface of the filter) were removed and invaded 
cells (on the lower surface of the filter) were stained with 
0.5% crystal violet. The invaded cells were visualized 
under the microscope and counted by the image-J. The 
number of seeding cells was adjusted by the trypan blue 
(Seeding cells = 2 × 104 cells/cell viability rate).
Mesothelial clearance assay
The SKOV3 cells in monolayer were labelled 
with CellTracker™ Oregon Green 488 (1 μg/ml, 37°C, 
20 minutes) (Life Technologies) and subjected to the 
sphere formation, followed by curcumin treatment (30 μM) 
for 48 hours. The LP-9 cells (A human-derived peritoneal 
mesothelial cell line) were purchased from ATCC 
(Rockville, MD, USA), and cultured in a 96-well plate 
with a ratio of Medium199 (Sigma-Aldrich) and Medium 
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MCDB 105 (Sigma-Aldrich) supplemented with 10% FCS, 
100 μg/ml streptomycin, and 100 U/ml penicillin to form 
confluent monolayers. The mesothelial cells labelled with 
CellTracker™ Orange CMRA (1 μg/ml, 37°C, 20 minutes), 
then the spheroids were transferred atop of the confluent 
monolayer of LP-9 gently (in 6 replicates per condition) 
and co-cultured for 24 hours. Each well was examined 
on an Olympus microscope and photographed using a 
Hamamatsu digital camera at the time points of 0 hour and 
24 hours. The nonfluorescent area, created by the invading 
spheroid, in the CellTrackerTM Orange CMRA labelled 
mesothelial monolayer images were measured at 24 hours 
and divided by the initial area of the spheroid at time 0 
(Clearance Area = Clearance Area24h / Clearance Area0h).
Statistical analysis
All experiments were at least repeated three times. All 
data were expressed as means ± SEM; Statistical analysis 
was performed on the variables in this study using either the 
Student’s two-tailed t-test or one-way ANOVA. A P-value 
< 0.05 was considered to indicate a statistically significant 
result. Graphpad Prism® (Version 4.03, GraphPad Software, 
San Diego California USA, http://www.graphpad.com) 
were used for data and graphic analysis.
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